Eikonoklastes Therapeutics

Executive Summary

Eikonoklastes Therapeutics is a preclinical-stage biotechnology company developing gene therapies for neurodegenerative diseases, with an initial focus on amyotrophic lateral sclerosis (ALS). The company's platform aims to enable rapid, disease-modifying treatments by leveraging accelerated regulatory pathways. Despite being in early development, Eikonoklastes addresses a significant unmet need in ALS, where current therapies offer limited efficacy. The company's approach involves a novel gene therapy designed to target disease mechanisms, potentially offering a one-time treatment. Eikonoklastes is based in Cambridge, MA, and was founded in 2019. It has not yet disclosed funding amounts or valuation, indicating a private, early-stage profile. The company's success hinges on preclinical proof-of-concept and successful IND enabling studies, with no public data available to date. If successful, its platform could extend to other neurological conditions, broadening its impact. However, pre-clinical stage implies high technical and regulatory risk. The company's ability to secure financing and advance its lead program into clinical trials will be critical near-term milestones.

Upcoming Catalysts (preview)

• H2 2026IND Filing for ALS Gene Therapy25% success
• Q3 2026Preclinical Proof-of-Concept Data in Animal Models40% success
• H1 2026Series A Funding Announcement50% success